The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
VJOncology avatar; VJ Oncology @VJOncology ·
December 8, 2023 1733079052628488564

It’s day 4 of SABCS 2023! Today, we’ll be hearing about recent advances in triple negative breast cancer ❗️🔬

http://VJOncology.com will have all the updates from SABCS shortly! 💻

#SABCS23 #BreastCancer #BCsm @SABCSSanAntonio @aacr

Image for the Tweet beginning: It’s day 4 of SABCS Twitter feed image.
Reply on Twitter 1733079052628488564 Retweet on Twitter 1733079052628488564 0 Like on Twitter 1733079052628488564 2 Twitter 1733079052628488564
VJOncology avatar; VJ Oncology @VJOncology ·
December 7, 2023 1732830556663013682

📽️@VJOncology are really enjoying catching up on all of the great research going on in #breastcancer at #SABCS23

See our latest coverage here 👉https://www.vjoncology.com/event/sabcs-2023/

#bcsm

Image for the Tweet beginning: 📽️@VJOncology are really enjoying catching Twitter feed image.
Reply on Twitter 1732830556663013682 Retweet on Twitter 1732830556663013682 0 Like on Twitter 1732830556663013682 2 Twitter 1732830556663013682
VJOncology avatar; VJ Oncology @VJOncology ·
December 6, 2023 1732438428652879999

It was a pleasure speaking with @VKaklamani of @UTHealthSA and co-director of #SABCS23 yesterday who discussed key take-home messages from the meeting

@SABCSSanAntonio @AACR #BreastCancer #BCsm @OncoAlert

Image for the Tweet beginning: It was a pleasure speaking Twitter feed image.
Reply on Twitter 1732438428652879999 Retweet on Twitter 1732438428652879999 1 Like on Twitter 1732438428652879999 7 Twitter 1732438428652879999
VJOncology avatar; VJ Oncology @VJOncology ·
December 6, 2023 1732339173359538395

It’s day 2 of SABCS 2023! On the agenda today is a state-of-the-art immunotherapy showcase session 💊❗️

Keep up to date with everything SABCS related on http://VJOncology.com 💻

#SABCS23 #BreastCancer #BCsm @SABCSSanAntonio @aacr #ImmunoOnc

Image for the Tweet beginning: It’s day 2 of SABCS Twitter feed image.
Reply on Twitter 1732339173359538395 Retweet on Twitter 1732339173359538395 0 Like on Twitter 1732339173359538395 0 Twitter 1732339173359538395
Load More

ASCO 2022

American Society for Clinical Oncology Annual Meeting 2022
03–07 June 2022 | Chicago, IL, and Online
The 2022 ASCO Annual Meeting, held in Chicago, IL showcased the latest research in cancer care. This year's programme featured several sessions complementing the meeting's theme: Advancing Equitable Cancer Care Through Innovation. Key trial updates include the practice-changing results of DESTINY-Breast04, PARADIGM as well as the novel KRASG12C inhibitor adagrasib, in non-small cell lung cancer.
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
December 8, 2023 1733079052628488564

It’s day 4 of SABCS 2023! Today, we’ll be hearing about recent advances in triple negative breast cancer ❗️🔬

http://VJOncology.com will have all the updates from SABCS shortly! 💻

#SABCS23 #BreastCancer #BCsm @SABCSSanAntonio @aacr

Image for the Tweet beginning: It’s day 4 of SABCS Twitter feed image.
Reply on Twitter 1733079052628488564 Retweet on Twitter 1733079052628488564 0 Like on Twitter 1733079052628488564 2 Twitter 1733079052628488564
VJOncology avatar; VJ Oncology @VJOncology ·
December 7, 2023 1732830556663013682

📽️@VJOncology are really enjoying catching up on all of the great research going on in #breastcancer at #SABCS23

See our latest coverage here 👉https://www.vjoncology.com/event/sabcs-2023/

#bcsm

Image for the Tweet beginning: 📽️@VJOncology are really enjoying catching Twitter feed image.
Reply on Twitter 1732830556663013682 Retweet on Twitter 1732830556663013682 0 Like on Twitter 1732830556663013682 2 Twitter 1732830556663013682
VJOncology avatar; VJ Oncology @VJOncology ·
December 6, 2023 1732438428652879999

It was a pleasure speaking with @VKaklamani of @UTHealthSA and co-director of #SABCS23 yesterday who discussed key take-home messages from the meeting

@SABCSSanAntonio @AACR #BreastCancer #BCsm @OncoAlert

Image for the Tweet beginning: It was a pleasure speaking Twitter feed image.
Reply on Twitter 1732438428652879999 Retweet on Twitter 1732438428652879999 1 Like on Twitter 1732438428652879999 7 Twitter 1732438428652879999
VJOncology avatar; VJ Oncology @VJOncology ·
December 6, 2023 1732339173359538395

It’s day 2 of SABCS 2023! On the agenda today is a state-of-the-art immunotherapy showcase session 💊❗️

Keep up to date with everything SABCS related on http://VJOncology.com 💻

#SABCS23 #BreastCancer #BCsm @SABCSSanAntonio @aacr #ImmunoOnc

Image for the Tweet beginning: It’s day 2 of SABCS Twitter feed image.
Reply on Twitter 1732339173359538395 Retweet on Twitter 1732339173359538395 0 Like on Twitter 1732339173359538395 0 Twitter 1732339173359538395
Load More

Late-Breaking Abstracts at ASCO 2022!

View all
1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022

Latest videos from ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
2:35
Adjuvant therapy in RCC: harnessing prognostic information
Pavlos Msaouel • 3 Jun 2022
1:22
KRYSTAL-1: activity and safety of adagrasib in patients with advanced/metastatic KRASG12Cm NSCLC
Alexander Spira • 3 Jun 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022

Breast Cancer at ASCO 2022

View all
0:51
What to look forward to in breast cancer at ASCO 2022?
Kevin Kalinsky • 3 Jun 2022
0:53
postMONARCHE: abemaciclib + fulvestrant in HR+/HER2- MBC following CDK4/6i & endocrine therapy
Kevin Kalinsky • 3 Jun 2022
1:46
ctDNA and late recurrence in high-risk, HR+, HER2- breast cancer
Marla Lipsyc-Sharf • 4 Jun 2022
0:48
MAINTAIN: fulvestrant or exemestane +/- ribociclib after anti-estrogen therapy + CDK4/6i in HR+ MBC
Kevin Kalinsky • 3 Jun 2022

GU at ASCO 2022

View all
1:32
Key trials in prostate cancer at ASCO 2022
Arun Azad • 27 May 2022
0:49
Current standards in BCG-unresponsive carcinoma in-situ and papillary NMIBC
Karim Chamie • 3 Jun 2022
2:19
Final results from ATLANTIS cabozantinib arm for urothelial carcinoma
Robert Jones • 4 Jun 2022
1:12
JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer
Joaquim Bellmunt • 4 Jun 2022
The content of VJOncology is intended for healthcare professionals